Passage Bio to Present at H.C. Wainwright Investment Conference
Passage Bio, Inc. (NASDAQ: PASG), a leader in the field of genetic medicines, has announced an exciting opportunity for both investors and the medical community to engage with its innovative leadership. The company will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference. During this important event, Will Chou, M.D., the president and chief executive officer, will provide insights into the company's mission and its cutting-edge approaches to treating neurodegenerative diseases.
Details of the Event
Be sure to mark your calendars for this significant presentation, which is scheduled for 7:00 a.m. ET. Attendees will have the opportunity to learn about the advancements that Passage Bio is making in the realm of genetic therapies. For those who are unable to attend the live session, a live webcast will be available, ensuring that all interested parties can stay updated.
About Passage Bio
Passage Bio is dedicated to improving the lives of individuals affected by neurodegenerative diseases through innovative research and development. The company focuses on delivering solutions that address the core challenges of these conditions, with a primary goal of creating transformative, one-time therapies that enhance patient outcomes.
Leading Innovations in Genetic Medicine
At the heart of Passage Bio's initiatives is its lead product candidate, PBFT02. This promising therapy is specifically designed to address neurodegenerative disorders, particularly frontotemporal dementia. By increasing progranulin levels in patients, PBFT02 seeks to restore lysosomal function and slow the progression of the disease, representing a significant advancement in treatment options.
Commitment to Patients and Families
Passage Bio's commitment extends beyond merely developing treatments; it is about providing hope and meaningful support to families facing the challenges of neurodegenerative conditions. The company is steadfast in its dedication to enhancing the quality of life for patients and their loved ones.
Connecting with the Community
For those interested in following the progress and achievements of Passage Bio, the company encourages you to visit their website. There, you will find comprehensive information about their initiatives and ongoing research efforts, showcasing their unwavering commitment to the health and well-being of patients.
Contact Information
If you would like more information, Passage Bio has a team of dedicated professionals ready to assist you. For investor inquiries, you can reach Stuart Henderson at 267.866.0114, or connect via email. For media inquiries, Mike Beyer from Sam Brown Inc. Healthcare Communications is also available to help.
Frequently Asked Questions
What is Passage Bio's focus in the medical field?
Passage Bio is focused on developing genetic medicines to enhance the lives of patients suffering from neurodegenerative diseases.
Who will be presenting at the conference?
Will Chou, M.D., the CEO of Passage Bio, will be the presenter at the H.C. Wainwright Investment Conference.
What is PBFT02?
PBFT02 is Passage Bio's lead product candidate, aimed at treating frontotemporal dementia by restoring lysosomal function.
How can I watch the presentation?
A live webcast of the presentation will be accessible on the Investors & Media section of Passage Bio’s website.
Who can I contact for further information?
For inquiries, you can reach out to Stuart Henderson for investor-related questions or Mike Beyer for media inquiries.
